Results 41 to 50 of about 7,855 (224)
The Scientific World Journal, 2013 Edaravone is a free radical scavenger that protects the adjacent cortex during cerebral infarction. We created a hemiparetic model of cerebral thrombosis from a photochemically induced infarction with the photosensitive dye, rose bengal, in rats.
Satoshi Ikeda +3 more
doaj +1 more source
STING deficiency promotes motor recovery in mice following brachial plexus root avulsion
Animal Models and Experimental Medicine, EarlyView.STING deficiency can increase the body weight, promote motor recovery, decrease MN death, inhibit pyroptosis and neuroinflammation, increase remyelination, and reduce the atrophy of the biceps brachii in mice with BPRA. Abstract Background Brachial plexus root avulsion (BPRA), a well‐known form of peripheral nerve injury, results in motor function loss
Yu Peng +4 more
wiley +1 more source
The protective effect of Edaravone against acute renocardiac syndrome in a kidney ischemia-reperfusion model [PDF]
Journal of Cardiovascular and Thoracic ResearchIntroduction: Acute kidney injury (AKI) is a common clinical occurrence causing high mortality and morbidity. In acute renocardiac syndrome, AKI leads to acute cardiac injury or/and dysfunction.
Yasin Bagheri +5 more
doaj +1 more source
Infusion & Chemotherapy, 2023 BACKGROUND. Edaravone is a free radical scavenger and inhibits lipid peroxidation and thus reduces oxidative damage to brain cells and other organs.
O.A. Halushko
doaj +1 more source
Back Again to the Future: A New Era for Cerebroprotection
Annals of Neurology, EarlyView.Cerebroprotection is a fresh framework for designing neurological therapy that targets glia and vascular cells, in addition to neurons. In the future, successful cerebroprotection will involve targeting all elements of the neurovascular unit. Preclinical trials must include functional outcomes, as well as lesion morphometry.
Patrick Lyden
wiley +1 more source
Efficacy of Edaravone in Cardioembolic Stroke
Internal Medicine, 2006 We investigated the efficacy of edaravone in patients with cardioembolic stroke.Cardioembolic stroke patients were treated with drip intravenous infusion of edaravone (ED group, n=141) for 7 days, and were retrospectively compared with a historical-controlled cohort of similar patients (control group, n=114).Early improvement (between day 0 and day 10),
Yuichiro, Inatomi +6 more
openaire +3 more sources
Annals of Neurology, EarlyView.Objective Biomarkers with clear contexts of use are important tools for amyotrophic lateral sclerosis (ALS) therapy development. Understanding their longitudinal trajectory in the untreated state is key to their use as potential markers of pharmacodynamic response.
Oleksandr Dergai +16 more
wiley +1 more source
PharmaceuticsEdaravone is one of two main drugs for treating motor neurone disease (MND). This review proposes a specific quality target product profile (QTPP) for edaravone following an appraisal of the issues accounting for the poor clinical uptake of the approved ...
Riuna O’Neill +3 more
doaj +1 more source
Journal of Pharmacological Sciences, 2007 We examined whether edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a free radical scavenger, exerts its protective effect on coronary microvessels after ischemia/reperfusion (I/R) in vivo.
Renan Sukmawan +9 more
doaj +1 more source
Edaravone protects against hyperosmolarity-induced oxidative stress and apoptosis in primary human corneal epithelial cells. [PDF]
PLoS ONE, 2017 An increase in the osmolarity of tears induced by excessive evaporation of the aqueous tear phase is a major pathological mechanism behind dry eye. Exposure of epithelial cells on the surface of the human eye to hyperosmolarity leads to oxidative stress,
Yanwei Li +3 more
doaj +1 more source